

Referenceliste til artikel i Dansk Sportsmedicin nr. 3, 2012:

Muskuloskeletal smerte: Fysiologi, manifestationer og mekanismer

Af:

Søren Thorgaard Skou, forskningsfysioterapeut og cand.scient., ph.d.-studerende

Lars Arendt-Nielsen, dr.med., PhD, professor

Thomas Graven-Nielsen, dr.med., PhD, professor

1. Bove SE, Flatters SJ, Inglis JJ, Mantyh PW. New advances in musculoskeletal pain. *Brain Res Rev* 2009; 60 (1): 187–201.
2. Das SK, Farooqi A. Osteoarthritis. *Best Practice and Research Clinical Rheumatology* 2008;22 (4):657–75.
3. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. *Eur J Pain*. 2006 May;10(4):287-333. Epub 2005 Aug 10.
4. Gibofsky A, Barkin RL. Chronic pain of osteoarthritis: considerations for selecting an extended-release opioid analgesic. *Am J Ther* 2008;15 (3):241–55.
5. Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals EK, et al. Assessment of pain. *Br J Anaesth* 2008;101 (1):17–24.
6. Read SJ, Dray A. Osteoarthritic pain: a review of current, theoretical and emerging therapeutics. *Expert Opin Investig Drugs* 2008;17 (5):619–40.
7. Kotlarz H, Gunnarsson CL, Fang H, Rizzo JA. Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data. *Arthritis & Rheum* 2009;60(12):3546–53.
8. Laine L, White WB, Rostom A, Hochberg M. COX-2 selective inhibitors in the treatment of osteoarthritis. *Semin Arthritis Rheum* 2008;38 (3):165–87.
9. Arendt-Nielsen L, Graven-Nielsen T. Translational musculoskeletal pain research. *Best Pract Res Clin Rheumatol* 2011; 25(2):209-26.
10. Graven-Nielsen T, Arendt-Nielsen L. Assessment of mechanisms in localized and widespread musculoskeletal pain. *Nat Rev Rheumatol* 2010;6(10):599–606.
11. Wylde V, Dieppe P, Hewlett S, Learmonth ID. Total knee replacement: is it really an effective procedure for all? *Knee* 2007; 14(6):417–423.
12. Beswick AD, Wylde V, Goberman-Hill R, Blom A, Dieppe P: What proportion of patients report long-term pain after total hip or knee replacement for osteoarthritis? A systematic review of prospective studies in unselected patients. *BMJ Open* 2012; 2(1):e000435.
13. Arendt-Nielsen L, Curatolo M, Drewes A. Human experimental pain models in drug development: translational pain research. *Curr Opin Investig Drugs* 2007;8 (1):41–53.
14. Curatolo M, Arendt-Nielsen L, Petersen-Felix S. Central hypersensitivity in chronic pain: mechanisms and clinical implications. *Phys Med Rehabil Clin N Am* 2006;17 (2):287–302.

15. Fernandez-Carnero J, Fernandez-de-las-Penas C, de la Llave-Rincon AI. Prevalence of and referred pain from myofascial trigger points in the forearm muscles in patients with lateral epicondylalgia. *Clin J Pain* 2007; 23 (4):353–60.
16. Ge HY, Fernandez-de-las-Penas C, Madeleine P, Arendt-Nielsen L. Topographical mapping and mechanical pain sensitivity of myofascial trigger points in the infraspinatus muscle. *Eur J Pain*. 2008;12 (7):859–65.
17. Graven-Nielsen T, Arendt-Nielsen L. Impact of clinical and experimental pain on muscle strength and activity. *Curr Rheumatol Rep* 2008;10 (6):475–81.
18. Nie H, Graven-Nielsen T, Arendt-Nielsen L. Spatial and temporal summation of pain evoked by mechanical pressure stimulation. *Eur J Pain* 2009;13(6):592–9.
19. Arendt-Nielsen L, Graven-Nielsen T. Translational aspects of musculoskeletal pain: from animals to patients. I: Graven-Nielsen T, Arendt-Nielsen L, Mense S (red.). *Fundamentals of musculoskeletal pain*. IASP Press 2008; s. 347–66.
20. Herren-Gerber R, Weiss S, Arendt-Nielsen L, Petersen-Felix S, Di Stefano G, Radanov BP, et al. Modulation of central hypersensitivity by nociceptive input in chronic pain after whiplash injury. *Pain Med* 2004;5 (4):366–76.
21. Curatolo M, Arendt-Nielsen L, Petersen-Felix S. Evidence, mechanisms, and clinical implications of central hypersensitivity in chronic pain after whiplash injury. *Clin J Pain* 2004;20 (6):469–76.
22. Arendt-Nielsen L, Graven-Nielsen T. Deep tissue hyperalgesia. *J Musculoskeletal Pain* 2002;10 (1-2):97–119.
23. Mense S. Nociception from skeletal muscle in relation to clinical muscle pain. *Pain* 1993;54 (3):241–89.
24. Molander C, Ygge J, Dalsgaard CJ. Substance P-, somatostatin- and calcitonin gene-related peptide-like immunoreactivity and fluoride resistant acid phosphatase-activity in relation to retrogradely labeled cutaneous, muscular and visceral primary sensory neurons in the rat. *Neurosci Lett* 1987;74(1):37–42.
25. Reinert A, Kaske A, Mense S. Inflammation-induced increase in the density of neuropeptide-immunoreactive nerve endings in rat skeletal muscle. *Exp Brain Res* 1998;121(2):174–80.
26. Graven-Nielsen T, Sergerdahl M, Svensson P, and Arendt-Nielsen L 2010. Methods for induction and assessment of pain in humans with clinical and pharmacological examples. I: Kruger L (red.), *Methods in Pain Research*. CRC Press 2010; s. 263-304.
27. Sessle BJ, Hu JW, Yu XM. Brainstem mechanisms of referred pain and hyperalgesia in the orofacial and temporomandibular region. I: Vecchiet L, Albe-Fessard D, Lindblom U, Giamberardino MA (red.). *New trends in referred pain and hyperalgesia*. Elsevier Science Publishers B.V. 1993; s. 59–71.
28. Mense S, Hoheisel U. Mechanisms of central nervous hyperexcitability due to activation of muscle nociceptors. I: Graven-Nielsen T, Arendt-Nielsen L, Mense S (red.). *Fundamentals of musculoskeletal pain*. IASP Press 2008; s. 61–73.
29. Marchettini P, Simone DA, Caputi G, Ochoa JL. Pain from excitation of identified muscle nociceptors in humans. *Brain Res* 1996;740(1-2):109–16.
30. Simone DA, Marchettini P, Caputi G, Ochoa JL. Identification of muscle afferents subserving sensation of deep pain in humans. *J Neurophysiol* 1994;72(2):883–9.
31. Jensen TS, Dahl JB, Arendt-Nielsen L, Bak FW. Smertefysiologi. I: Jensen TS, Dahl JB, Arendt-Nielsen L (red.), *Smerter: baggrund, evidens og behandling*. FADL 2009, s. 23-36.
32. Schibye B, Klausen K. Menneskets fysiologi: hvile og arbejde. FADL 2005.

33. Carli G, Suman AL, Biasi G, Marcolongo R. Reactivity to superficial and deep stimuli in patients with chronic musculoskeletal pain. *Pain* 2002;100 (3):259–69.
34. Fernández-de-las-Peñas C, Ge HY, Arendt-Nielsen L, Cuadrado ML, Pareja JA. The local and referred pain from myofascial trigger points in the temporalis muscle contributes to pain profile in chronic tension type headache. *Clin J Pain* 2007;23(9):786–92.
35. Smart KM, Blake C, Staines A, Doody C. Clinical indicators of ‘nociceptive’, ‘peripheral neuropathic’ and ‘central’ mechanisms of musculoskeletal pain. A Delphi survey of expert clinicians. *Man Ther* 2010; 15(1): 80–87.
36. Nijs J, Van Houdenhove B, Oostendorp R. A. Recognition of central sensitization in patients with musculoskeletal pain: application of pain neurophysiology in manual therapy practice. *Man Ther* 2010; 15(2): 135–141.
37. Luginbuhl M, Schnider TW, Petersen-Felix S, Arendt-Nielsen L, Zbinden AM. Comparison of five experimental pain tests to measure analgesic effects of alfentanil. *Anesthesiology* 2001; 95(1):22-29.
38. Neziri AY, Curatolo M, Nuesch E, Scaramozzino P, Andersen OK, Arendt-Nielsen L, Juni P. Factor analysis of responses to thermal, electrical, and mechanical painful stimuli supports the importance of multi-modal pain assessment. *Pain* 2011; 152(5):1146-1155.
39. Skou ST, Graven-Nielsen T, Lengsoe L, Simonsen O, Laursen MB, Arendt-Nielsen L. Predicting clinical pain in knee osteoarthritis using a multimodal pressure pain assessment procedure. *IASP* 2012; Abstract 161.
40. Binderup AT, Arendt-Nielsen L, Madeleine P. Cluster analysis of pressure pain threshold maps from the trapezius muscle. *Comput Methods Biomech Biomed Engin* 2010; 13(6):677-83
41. Arendt-Nielsen L, Nie H, Laursen MB, Laursen BS, Madeleine P, Simonsen OH, Graven-Nielsen T. Sensitization in patients with painful knee osteoarthritis. *Pain* 2010;149(3):573–81.
42. Hoheisel U, Koch K, Mense S. Functional reorganization in the rat dorsal horn during an experimental myositis. *Pain* 1994;59(1):111–8.
43. Hoheisel U, Sardy M, Mense S. Experiments on the nature of the signal that induces spinal neuroplastic changes following a peripheral lesion. *Eur J Pain* 1997;1(4):243–59.
44. Hoheisel U, Mense S, Simons DG, Yu M. Appearance of new receptive fields in rat dorsal horn neurons following noxious stimulation of skeletal muscle: a model for referral of muscle pain? *Neurosci Lett* 1993;153(1):9–12.
45. Mense S. Referral of muscle pain. New aspects. *APS J* 1994;3(1):1–9.
46. Graven-Nielsen T. Fundamentals of muscle pain, referred pain, and deep tissue hyperalgesia. *Scand J Rheumatol* 2006;35(suppl.122):1–43.
47. Kellgren JH. Observations on referred pain arising from muscle. *Clin Sci* 1938;3:175–90.
48. Feinstein B, Langton JNK, Jameson RM, Schiller F. Experiments on pain referred from deep somatic tissues. *J Bone Joint Surg Am* 1954;36-A(5):981-97.
49. Steinbrocker O, Isenberg SA, Silver M, Neustadt D, Kuhn P, Schittone M. Observations on pain produced by injections of hypertonic saline into muscles and other supportive tissues. *J Clin Invest* 1953;32(10):1045–51.
50. Graven-Nielsen T, Arendt-Nielsen L, Svensson P, Jensen TS. Stimulus-response functions in areas with experimentally induced referred muscle pain – a psychophysical study. *Brain Res* 1997;744(1):121–8.
51. Graven-Nielsen T, Babenko V, Svensson P, Arendt-Nielsen L. Experimentally induced muscle pain induces hypoalgesia in heterotopic deep tissues, but not in homotopic deep tissues. *Brain Res* 1998;787(2):203–10.

52. Laursen RJ, Graven-Nielsen T, Jensen TS, Arendt-Nielsen L. The effect of compression and regional anaesthetic block on referred pain intensity in humans. *Pain* 1999;80(1-2):257–63.
53. Laursen RJ, Graven-Nielsen T, Jensen TS, Arendt-Nielsen L. Quantification of local and referred pain in humans induced by intramuscular electrical stimulation. *Eur J Pain* 1997;1(2):105–13.
54. Schulte H, Graven-Nielsen T, Sollevi A, Jansson Y, Arendt-Nielsen L, Segerdahl M. Pharmacological modulation of experimental phasic and tonic muscle pain by morphine, alfentanil and ketamine in healthy volunteers. *Acta Anaesthesiol Scand* 2003;47(8):1020–30.
55. Dickenson AH, Sullivan AF. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation. *Neuropharmacology* 1987;26(8):1235–8.
56. Laursen BS, Bajaj P, Olesen AS, Delmar C, Arendt-Nielsen L. Health related quality of life and quantitative pain measurement in females with chronic non-malignant pain. *Eur J Pain* 2005;9(3):267–75.
57. Banic B, Petersen-Felix S, Andersen OK, Radanov BP, Villiger PM, Arendt-Nielsen L, Curatolo M. Evidence for spinal cord hypersensitivity in chronic pain after whiplash injury and in fibromyalgia. *Pain* 2004;107(1-2):7–15.
58. Neziri AY, Haesler S, Petersen-Felix S, Müller M, Arendt-Nielsen L, Manresa JB, Andersen OK, Curatolo M. Generalized expansion of nociceptive reflex receptive fields in chronic pain patients. *Pain*; 2010; 151(3):798-805.
59. Morris V, Cruwys S, Kidd B. Increased capsaicin-induced secondary hyperalgesia as a marker of abnormal sensory activity in patients with fibromyalgia. *Neurosci Lett* 1998;250(3):205–7.
60. Morris VH, Cruwys SC, Kidd BL. Characterisation of capsaicin-induced mechanical hyperalgesia as a marker for altered nociceptive processing in patients with rheumatoid arthritis. *Pain* 1997;71(2):179–86.
61. Bajaj P, Graven-Nielsen T, Arendt-Nielsen L. Trigger points in patients with lower limb osteoarthritis. *J Musculoskelet Pain* 2001;9(3):17–33.
62. Slater H, Arendt-Nielsen L, Wright A, Graven-Nielsen T. Sensory and motor effects of experimental muscle pain in patients with lateral epicondylalgia and controls with delayed onset muscle soreness. *Pain* 2005;114(1-2):118–30.
63. Bajaj P, Bajaj P, Graven-Nielsen T, Arendt-Nielsen L. Osteoarthritis and its association with muscle hyperalgesia: an experimental controlled study. *Pain* 2001;93(2):107–14.
64. Johansen MK, Graven-Nielsen T, Olesen AS, Arendt-Nielsen L. Generalised muscular hyperalgesia in chronic whiplash syndrome. *Pain* 1999;83(2):229–34.
65. Sörensen J, Graven-Nielsen T, Henriksson KG, Bengtsson M, Arendt-Nielsen L. Hyperexcitability in fibromyalgia. *J Rheumatol* 1998;25(1):152–5.
66. O'Neill S, Manniche C, Graven-Nielsen T, Arendt-Nielsen L. Generalized deep-tissue hyperalgesia in patients with chronic low-back pain. *Eur J Pain* 2007;11(4):415–20.
67. Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, Bengtsson M, Sörensen J, Johnson A, Gerdle B, Arendt-Nielsen L. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. *Pain* 2000;85(3):483–91.
68. Arendt-Nielsen L, Graven-Nielsen T. Central sensitization in fibromyalgia and other musculoskeletal disorders. *Curr Pain Headache Rep* 2003;7(5):355–61.
69. Schouenborg J, Sjolund BH. Activity evoked by A- and C-afferent fibers in rat dorsal horn neurons and its relation to a flexion reflex. *J Neurophysiol* 1983;50(5):1108–21.

70. Woolf CJ. Windup and central sensitization are not equivalent. *Pain* 1996;66(2-3):105–8.
71. Cervero F, Shouenborg J, Sjolund BH, Waddell PJ. Cutaneous inputs to dorsal horn neurones in adult rats treated at birth with capsaicin. *Brain Res* 1984;301(1):47–57.
72. Graven-Nielsen T, Arendt-Nielsen L, Svensson P, Jensen TS. Quantification of local and referred muscle pain in humans after sequential i.m. injections of hypertonic saline. *Pain* 1997;69(1-2):111–7.
73. Nie H, Arendt-Nielsen L, Madeleine P, Graven-Nielsen T. Enhanced temporal summation of pressure pain in the trapezius muscle after delayed onset muscle soreness. *Exp Brain Res* 2006;170(2):182–90.
74. Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Giani C, Zbinden AM, Radanov BP. Central hypersensitivity in chronic pain after whiplash injury. *Clin J Pain* 2001;17(4):306–15.
75. Cathcart S, Winefield AH, Rolan P, Lushington K. Reliability of temporal summation and diffuse noxious inhibitory control. *Pain Res Manag* 2009;14(6):433-438.
76. Wen YR, Wang CC, Yeh GC, Hsu SF, Huang YJ, Li YL, Sun WZ. DNIC-mediated analgesia produced by a supramaximal electrical or a high-dose formalin conditioning stimulus: roles of opioid and alpha2-adrenergic receptors. *J Biomed Sci* 2010; 17(1):19.
77. Millan MJ. Descending control of pain. *Prog Neurobiol* 2002;66:355–474.
78. Vanegas H, Schaible HG. Descending control of persistent pain: inhibitory or facilitatory? *Brain Res Brain Res Rev* 2004;46(3):295–309.
79. Yarnitsky D, Arendt-Nielsen L, Bouhassira D, Edwards RR, Fillingim RB, Granot M, Hansson P, Lautenbacher S, Marchand S, Wilder-Smith O. Recommendations on terminology and practice of psychophysical DNIC testing. *Eur J Pain* 2010;14(4):339.
80. Arendt-Nielsen L, Gotliebsen K. Segmental inhibition of laser-evoked brain potentials by ipsi- and contralaterally applied cold pressor pain. *Eur J Appl Physiol Occup Physiol* 1992;64(1):56–61.
81. Bouhassira D, Danziger N, Attal N, Guirimand F. Comparison of the pain suppressive effects of clinical and experimental painful conditioning stimuli. *Brain* 2003;126(Pt 5):1068–78.
82. Bragdon EE, Light KC, Costello NL, Sigurdsson A, Bunting S, Bhalang K, Maixner W. Group differences in pain modulation: pain-free women compared to pain-free men and to women with TMD. *Pain* 2002;96(3):227–37.
83. King CD, Wong F, Currie T, Mauderli AP, Fillingim RB, Riley JL 3rd. Deficiency in endogenous modulation of prolonged heat pain in patients with Irritable Bowel Syndrome and Temporomandibular Disorder. *Pain* 2009;143(3):172-178.
84. Peters ML, Schmidt AJ, Van den Hout MA, Koopmans R, Sluijter ME. Chronic back pain, acute postoperative pain and the activation of diffuse noxious inhibitory controls (DNIC). *Pain* 1992;50(2):177–87.
85. Kosek E, Hansson P. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. *Pain* 1997;70(1):41–51.
86. Kosek E, Ordeberg G. Lack of pressure pain modulation by heterotopic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following, surgical pain relief. *Pain* 2000;88(1):69–78.
87. Sandrini G, Rossi P, Milanov I, Serrao M, Cecchini AP, Nappi G. Abnormal modulatory influence of diffuse noxious inhibitory controls in migraine and chronic tension-type headache patients. *Cephalalgia* 2006;26(7):782–9.

88. Leffler AS, Kosek E, Lerndal T, Nordmark B, Hansson P. Somatosensory perception and function of diffuse noxious inhibitory controls (DNIC) in patients suffering from rheumatoid arthritis. *Eur J Pain* 2002;6(2):161–76.
89. Ge HY, Madeleine P, Arendt-Nielsen L. Sex differences in temporal characteristics of descending inhibitory control: an evaluation using repeated bilateral experimental induction of muscle pain. *Pain* 2004;110(1-2):72–8. [87]
90. Cairns BE, Svensson P, Wang K, Castrillon E, Hupfeld S, Sessle BJ, et al. Ketamine attenuates glutamate-induced mechanical sensitization of the masseter muscle in human males. *Exp Brain Res* 2006;169(4):467–72.
91. Ernberg M, Lundeberg T, Kopp S. Effect of propranolol and granisetron on experimentally induced pain and allodynia/hyperalgesia by intramuscular injection of serotonin into the human masseter muscle. *Pain* 2000;84(2-3):339–46.
92. Slater H, Arendt-Nielsen L, Wright A, Graven-Nielsen T. Experimental deep tissue pain in wrist extensors - a model of lateral epicondylalgia. *Eur J Pain* 2003;7(3):277–88.
93. Andersen H, Arendt-Nielsen L, Danneskiold-Samsøe B, Graven-Nielsen T. Pressure pain sensitivity and hardness along human normal and sensitized muscle. *Somatosens Mot Res* 2006;23(3-4):97–109.
94. Svensson P, Cairns BE, Wang K, Arendt-Nielsen L. Injection of nerve growth factor into human masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia. *Pain* 2003;104(1-2):241–7.
95. Andersen H, Arendt-Nielsen L, Svensson P, Danneskiold-Samsøe B, Graven-Nielsen T. Spatial and temporal aspects of muscle hyperalgesia induced by nerve growth factor in humans. *Exp Brain Res* 2008;191(3):371–82.
96. Hoheisel U, Unger T, Mense S. Sensitization of rat dorsal horn neurons by NGF-induced subthreshold potentials and low-frequency activation. A study employing intracellular recordings in vivo. *Brain Res* 2007;1169:34–43.
97. Simons DG, Travell JG, Simons L. Myofascial pain and dysfunction. The trigger point manual. Lippincott Williams & Wilkins 1999.
98. Vecchiet L, Giamberardino MA, de Bigontina P, Dragani L. Comparative sensory evaluation of parietal tissues in painful and nonpainful areas in fibromyalgia and myofascial pain syndrome. I: Gebhart GF, Hammond DL, Jensen TS (red.). Proceedings of the 7th world congress on pain, vol. 2. IASP Press 1994; s. 177–85.
99. Andersen H, Ge H, Arendt-Nielsen L, Danneskiold-Samsøe B, Graven-Nielsen T. Increased trapezius pain sensitivity is not associated with increased tissue hardness. *J Pain* 2010;11(5):491–9.
100. Bjordal JM, Klovning A, Ljunggren AE, Slordal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials. *Eur J Pain* 2007; 11(2):125-138.
101. Esenyel M, İçağasioğlu A, Esenyel CZ. Effects of calcitonin on knee osteoarthritis and quality of life. *Rheumatol Int.* 2012 Mar 28. [Epub ahead of print].
102. Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. *Arthritis & Rheumatism* 2006;54(10):3205–11.
103. Schnitzer TJ, Lane NE, Smith MD, Brown MT. Efficacy and safety of PF04383119 for moderate to severe pain due to osteoarthritis (OA) of the knee: a randomized trial. IASP 2008; Abstract PT214.
104. Schnitzer TJ, Lane NE, Birbara CA, Smith MD, Simpson S, Brown MT. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. *Osteoarthritis Cartilage.* 2011 Jun;19(6):639-46.